• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Access to Healthcare

Living with hypertension in Cameroon on a few dollars per day

In Cameroon, seeking treatment for chronic diseases can be a long journey.

Sep 29, 2017

Every month, Alvine Nyintché travels 5 kilometers (about 3 miles) to the Etoug-Ebe Baptist Hospital in Yaoundé, the capital of Cameroon. Nyintché, age 50, was diagnosed with high blood pressure seven years ago.

Today, Nyintché has access to an affordable treatment thanks to Novartis Access, which provides a portfolio of medicines that help treat key chronic conditions. In Cameroon, these medicines will be available through some hospitals and clinics of the Cameroon Baptist Convention Health Services. The program will later be extended to other faith-based groups and eventually the entire country. Beyond medicines, activities will be conducted to strengthen healthcare systems. They include training healthcare professionals on how to manage noncommunicable diseases as well as providing community education and awareness. 

A memorandum of understanding has recently been signed between the Ministry of Health of Cameroon and Novartis, complementing efforts by the government to establish prevention and control programs for the growing burden of chronic diseases. These diseases – such as diabetes, hypertension (high blood pressure), cancer and respiratory diseases – are a growing concern in Cameroon, already causing an estimated 31% of deaths every year, according to the World Health Organization.1

Keep reading (or watch a video) to learn more about how cooperation between the Cameroonian government, faith-based organizations and Novartis Access is helping people like Nyintché.

A busy street in the middle of Yaoundé, Cameroon’s capital city.

Like many countries in Africa, Cameroon has experienced a rapid urbanization during the last decade leading to drastic changes in lifestyle. Stress, obesity, physical inactivity, poor eating habits and tobacco consumption are some of the factors that have led to the increase of chronic diseases such as diabetes, heart disease, cancer and chronic respiratory diseases.

Nyintché, age 50, was diagnosed with hypertension seven years ago.

“Most Cameroonians do not have medical insurance. Today, I pay 800 CFA francs [about USD 1.5] every month for my hypertension treatment, whereas just a few months back, it cost me 5 000 CFA francs [about USD 9]. I am a single mother. My two daughters are unemployed and we have to pay rent,” says Alvine Nyintché.

Nyintché lives in Briqueterie, one of the poorest neighborhoods in Yaoundé.

Nyintché lives in Briqueterie, one of the poorest neighborhoods in Yaoundé, the capital of Cameroon. The majority of Cameroonians live in poverty.

Nyintché, a single mother, lives with her two daughters and her granddaughter.

Nyintché shares a single room with her two daughters and grandchild that serves as both her bedroom and living room. She works every day to find solutions to feed herself and her family and to pay for her living expenses and medicine.

Nyintché prepares a pumpkin seed dish that she sells in the street.

Nyintché prepares a dish made of pumpkin seeds that she serves in banana leaves and sells in the street, making an income of barely USD 2 a day. “Sometimes I sell enough to cover all my costs, but other times the quantity is just not enough,” she says.

The Cameroon Baptist Convention Health Services in the Etoug-Ebe Baptist Hospital in Yaoundé

The Etoug-Ebe Baptist Hospital in Yaoundé is run by the Cameroon Baptist Convention Health Services. This is one of the first facilities where Novartis Access medicines are available to patients to treat conditions such as hypertension.

A patient evaluation for the Know Your Numbers campaign at the Cameroon Baptist Convention Health Services

A patient is being weighed at the Etoug-Ebe Baptist Hospital, one of 88 health facilities run by the Cameroon Baptist Convention (CBC) Health Services. As part of its partnership with Novartis Access, CBC Health Services has launched the Know Your Numbers campaign to encourage individuals to know their critical health numbers such as weight and blood pressure.

Cordel Ndasi, a nurse at the Etoug-Ebe Baptist Hospital, measures a patient’s blood pressure.

Cordel Ndasi, a nurse at the Etoug-Ebe Baptist Hospital, measures a patient’s blood pressure. She hopes patients will be more motivated to know their status if they also know they can have access to affordable medicines. “As a nurse, it pains my heart when I see someone coming in with complications. If this person had been diagnosed earlier, we could have given her a treatment to keep her healthy and productive,” she says.

Novartis Access medicines are already available through Cameroon Baptist Convention Health Services facilities in Yaoundé.

Getting high-quality treatments at an affordable price is an important element of the prevention and control programs put in place by the government of Cameroon to manage noncommunicable diseases.

Nyintché walks through the neighborhood in Briqueterie, Yaoundé.

Getting access to affordable treatment without having to travel long distances offers great hope to people like Nyintché and their families. This will help them take control of their health, sustaining themselves and their families.

 

  1. WHO: http://apps.who.int/iris/bitstream/10665/128038/1/9789241507509_eng.pdf

 

Shareline

Seeking treatment for hypertension when you make just a few dollars a day in Cameroon can be a long journey. #NovartisAccess
Tweet Tweetpopo

Novartis Access

Noncommunicable diseases (NCDs) are expected to overtake infectious diseases in low- and middle- income countries in the next two decades. Novartis Access focuses on the affordability and availability of 15 patented and generic medicines addressing four key NCDs.

Learn More

Tags: 
Access to Healthcare, Africa, Global Health Partnerships, Novartis Access, Novartis Social Business
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Dr. Theophile Tuyisabe standing next to his patients smiling at him
Access to Healthcare

Meet a visionary who beat the odds to realize his vision of inclusive eye care

Access to Healthcare

Chagas disease: Breaking the silence

Sandoz in Kalwe, India ensures multidrug therapy (MTD) supply to WHO to fight leprosy
Access to Healthcare

Ensuring medicine supply to patients during COVID-19

You are here

  1. Home ›
  2. Stories ›
  3. Access healthcare

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.